Cumberland Pharmaceuticals Inc. (CPIX): Price and Financial Metrics
CPIX Price/Volume Stats
Current price | $1.78 | 52-week high | $2.91 |
Prev. close | $1.65 | 52-week low | $1.43 |
Day low | $1.68 | Volume | 17,600 |
Day high | $2.03 | Avg. volume | 20,003 |
50-day MA | $1.85 | Dividend yield | N/A |
200-day MA | $1.79 | Market Cap | 25.38M |
CPIX Stock Price Chart Interactive Chart >
CPIX Stock Summary
- CPIX has a higher market value than just 10.57% of US stocks; more precisely, its current market capitalization is $23,949,576.
- The price/operating cash flow metric for CUMBERLAND PHARMACEUTICALS INC is higher than merely 8.97% of stocks in our set with a positive cash flow.
- CUMBERLAND PHARMACEUTICALS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 23.04%, greater than the shareholder yield of 92.06% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to CUMBERLAND PHARMACEUTICALS INC are KVHI, BELFA, BODY, TALK, and VOXX.
- CPIX's SEC filings can be seen here. And to visit CUMBERLAND PHARMACEUTICALS INC's official web site, go to www.cumberlandpharma.com.
CPIX Valuation Summary
- CPIX's price/earnings ratio is -10.1; this is 138.04% lower than that of the median Healthcare stock.
- CPIX's EV/EBIT ratio has moved down 52.3 over the prior 174 months.
Below are key valuation metrics over time for CPIX.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
CPIX | 2023-11-20 | 0.6 | 0.7 | -10.1 | -14.6 |
CPIX | 2023-11-17 | 0.6 | 0.7 | -9.8 | -14.2 |
CPIX | 2023-11-16 | 0.6 | 0.6 | -9.4 | -13.6 |
CPIX | 2023-11-15 | 0.6 | 0.6 | -9.6 | -13.8 |
CPIX | 2023-11-14 | 0.6 | 0.7 | -9.9 | -14.2 |
CPIX | 2023-11-13 | 0.6 | 0.6 | -9.5 | -13.7 |
CPIX Growth Metrics
- Its 2 year revenue growth rate is now at -16.69%.
- Its year over year cash and equivalents growth rate is now at -30.72%.
- The 4 year revenue growth rate now stands at 25.88%.

The table below shows CPIX's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 41.20713 | 6.775045 | -6.977209 |
2022-06-30 | 37.8666 | 4.037711 | -7.623848 |
2022-03-31 | 36.62293 | 4.406396 | -5.059668 |
2021-12-31 | 35.98504 | 6.342443 | -3.507587 |
2021-09-30 | 37.92672 | 5.236684 | -0.543665 |
2021-06-30 | 39.10486 | 6.19576 | 0.029876 |
CPIX Price Target
For more insight on analysts targets of CPIX, see our CPIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $8.50 | Average Broker Recommendation | 2 (Hold) |
Cumberland Pharmaceuticals Inc. (CPIX) Company Bio
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for the hospital acute care and gastroenterology markets in the United States and internationally. The company was founded in 1999 and is based in Nashville, Tennessee.
Latest CPIX News From Around the Web
Below are the latest news stories about CUMBERLAND PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CPIX as an investment opportunity.
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2023 Earnings Call TranscriptCumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2023 Earnings Call Transcript November 11, 2023 Operator: Good afternoon, and welcome to Cumberland Pharmaceuticals Third Quarter 2023 Company Update and Financial Report. This call is being recorded at Cumberland’s request and will be archived on the company’s website for one year from today’s date. I would now like to […] |
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial ResultsCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $10.1 million during the third quarter of 2023 and $30.2 million year to date. |
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTSCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financial results and provide a company update after the market closes on Tuesday, Nov. 7, 2023. |
NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGECumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today a new publication in Antimicrobial Agents and Chemotherapy1 detailing the results of the first clinical study investigating the safety and pharmacokinetics of Vibativ® (telavancin) injection in children 2 to 17 years of age. Vibativ is an intravenous antibiotic approved by the FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) as well as complicated skin and skin structure infections |
Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2023. |
CPIX Price Returns
1-mo | 6.59% |
3-mo | 10.56% |
6-mo | 5.95% |
1-year | -16.82% |
3-year | -40.47% |
5-year | -71.52% |
YTD | -20.89% |
2022 | -51.82% |
2021 | 58.31% |
2020 | -42.72% |
2019 | -14.59% |
2018 | -18.07% |
Continue Researching CPIX
Here are a few links from around the web to help you further your research on Cumberland Pharmaceuticals Inc's stock as an investment opportunity:Cumberland Pharmaceuticals Inc (CPIX) Stock Price | Nasdaq
Cumberland Pharmaceuticals Inc (CPIX) Stock Quote, History and News - Yahoo Finance
Cumberland Pharmaceuticals Inc (CPIX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...